SELLAS Life Sciences Group, Inc. (SLS)财务
NASDAQ · Healthcare · Biotechnology · 员工13人 · CEO Angelos Stergiou
- 股价
- $14.69 +2.0%
- 市值
- $27.8亿
- 企业价值
- $26.5亿 数据截至 2026-11-21
- 最近财报
- Q3 '26 2026-11-12提交
- 下次财报
- 2027-03-25 EPS预期 -$0.05
估值与关键数据
- 市值
- $27.8亿 3h 前更新
- 营收
- $0 过去12个月
- 营收增速
- – FY2026年一致预期
- 净利润率
- – 净利润 / 营收,TTM
- P/E
- 无市盈率 过去十二个月亏损
- P/S
- – 股价 / 营收,TTM
- EV / EBITDA
- -74.1× TTM
- 自由现金流
- -$2730万 过去12个月
- 净利润
- -$3580万 过去12个月
- 营收预期
- $3610万 FY2026年一致预期
- 盈利
- 2027-03-25 营收预估 $3610万 · 3h 前更新
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-11-12):营收无,EPS 符合预期营收–,预期–(–);EPS -$0.05,预期-$0.05(0.0%)。
- 稀释股数一年内增加86.8%Q3 '26稀释股数2.02亿,一年前为1.08亿。
- 净现金 $1.34亿现金 + 短期投资 $1.35亿,含租赁债务 $59.9万;一年前净现金 $4380万。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $0 | $0 | – |
| 营业利润 | -$1130万 | -$708万 | -59.7% |
| 净利润 | -$1010万 | -$679万 | -48.6% |
| 稀释EPS | -$0.05 | -$0.06 | +20.1% |
| 经营现金流 | -$594万 | -$707万 | +16.0% |
| 资本支出 | $0 | $0 | – |
| 自由现金流 | -$594万 | -$707万 | +16.0% |
| R&D | $703万 | $422万 | +66.7% |
| 股权激励费用 | $193万 | $50.3万 | +284.1% |
实际 vs 一致预期
2026-11-12| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| EPS(一致预期口径) | -$0.05 | -$0.05 | 0.0% |
来自2026-11-12发布的Q3 '26财报:营收及分析师预期口径的EPS(通常为调整后),可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$2730万
- 资本支出
- $0
- 股票回购
- $0
- 股息
- $0
- 收购
- $0
- 债务净发行
- $0
- 股权激励费用
- $419万
- 自由现金流
- -$2730万
- 股东回报 / FCF
- 0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | – | – | – |
| EV / EBITDA | -74.1× | 66.5× 5年中的2年 | 52.6× – 80.3× |
| EV / 营收 | 0.0× | 19.1× 5年中的2年 | 8.5× – 29.6× |
| 股价 / FCF | -102.0× | – | – |
| 股价 / 净资产 | 21.0× | 6.5× 5年中的4年 | 4.2× – 9.4× |
| FCF收益率 | -1.0% | -56.0% | -125.4% – -6.9% |
| 投入资本回报率 | -29.8% | -127.6% | -723.3% – 535.6% |
| 净资产收益率 | -31.9% | -169.8% | -851.4% – 468.2% |
分析师
一致目标价 $35.00 (+156.2%)
区间 $35.00 – $35.00 · 评级 Buy
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $3610万 | – | -$0.20 | +20.0% | – | 1 |
| FY2027 | $5470万 | +51.3% | -$0.25 | -22.5% | – | 2 |
| FY2028 | $7890万 | +44.3% | -$0.02 | +91.8% | – | 2 |
| FY2029 | $1.86亿 | +135.5% | $0.36 | +1,900.0% | 40.8× | 1 |
| FY2030 | $7.89亿 | +324.6% | $2.68 | +644.4% | 5.5× | 1 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
SELLAS Life Sciences Group, Inc.在近期10-Q / 10-K文件中标记的全部135项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| 应付账款 | $209万 | $231万 | -9.4% | $295万 | $350万 | -15.8% |
| 应计负债(流动) | $660万 | $302万 | +118.4% | $353万 | $547万 | -35.5% |
| Accrued Professional Fees, Current | $128万 | $22.4万 | +471.0% | $19万 | $30.8万 | -38.3% |
| 资本公积 | $4.35亿 | $3.13亿 | +39.0% | $3.46亿 | $2.58亿 | +34.3% |
| Administrative Fees Expense | $30万2026-07-24 | – | – | – | – | – |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | -161万 | -530万 | +69.7% | 6200万 | 5830万 | +6.5% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $193万 | $50.3万 | +284.1% | $196万 | $156万 | +25.1% |
| 总资产 | $1.41亿 | $5160万 | +173.7% | $7830万 | $1940万 | +303.2% |
| 流动资产 | $1.39亿 | $4910万 | +182.5% | $7520万 | $1630万 | +360.7% |
| 现金及现金等价物 | $1.35亿 | $4430万 | +204.0% | $7180万 | $1390万 | +417.0% |
| 现金、现金等价物及受限现金 | $1.35亿 | $4440万 | +203.5% | $7190万 | $1400万 | +414.0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$363万 | $1900万 | -119.1% | $5790万 | $1140万 | +409.9% |
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $1.69 | – | – | $0.75 | – | – |
| Class of Warrant or Right, Outstanding | 812万 | 6370万 | -87.2% | 5850万 | 5600万 | +4.5% |
| Common Stock, Capital Shares Reserved for Future Issuance | 3370万 | 7020万 | -51.9% | 6420万 | 6180万 | +3.9% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| 法定普通股 | 3.5亿 | 3.5亿 | 0.0% | 3.5亿 | 3.5亿 | 0.0% |
| 已发行普通股 | 2.04亿 | 1.25亿 | +62.7% | 1.53亿 | 7400万 | +107.0% |
| 流通在外普通股 | 2.04亿 | 1.25亿 | +62.7% | 1.53亿 | 7400万 | +107.0% |
| 普通股面值 | $2万 | $1.2万 | +66.7% | $1.5万 | $7000 | +114.3% |
| 销售成本 | $0 | $0 | – | $0 | $0 | – |
| Costs and Expenses | $1130万 | $708万 | +59.7% | $2830万 | $3150万 | -10.3% |
| Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | $02026-03-31 | $2.1万 | -100.0% | $1.7万 | $0 | – |
| Decrease in Unrecognized Tax Benefits is Reasonably Possible | $02025-12-31 | – | – | $0 | – | – |
| Deferred Tax Assets, Gross | $2300万2025-12-31 | $2110万 | +9.4% | $2300万 | $2110万 | +9.4% |
| Deferred Tax Assets, in Process Research and Development | $219万2025-12-31 | $250万 | -12.7% | $219万 | $250万 | -12.7% |
| Deferred Tax Assets, Net of Valuation Allowance | $20.8万2025-12-31 | $20万 | +4.0% | $20.8万 | $20万 | +4.0% |
| Deferred Tax Assets, Operating Loss Carryforwards | $1670万2025-12-31 | $1410万 | +18.5% | $1670万 | $1410万 | +18.5% |
| Deferred Tax Assets, Other | $35.5万2025-12-31 | $32.4万 | +9.6% | $35.5万 | $32.4万 | +9.6% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $79.7万2025-12-31 | $62.2万 | +28.1% | $79.7万 | $62.2万 | +28.1% |
| Deferred Tax Assets, Valuation Allowance | $2280万2025-12-31 | $2090万 | +9.5% | $2280万 | $2090万 | +9.5% |
| Deferred Tax Liabilities, Gross | $20.8万2025-12-31 | $20万 | +4.0% | $20.8万 | $20万 | +4.0% |
| Deferred Tax Liabilities, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Defined Benefit Plan, Plan Assets, Contributions by Employer | – | – | – | $11.7万 | $12.4万 | -5.6% |
| Deposits Assets, Noncurrent | $2.5万 | $3.4万 | -26.5% | $25.7万 | $26.6万 | -3.4% |
| 基本每股收益 | -$0.05 | -$0.06 | +16.7% | -$0.25 | -$0.50 | +50.0% |
| 稀释每股收益 | -$0.05 | -$0.06 | +16.7% | -$0.25 | -$0.50 | +50.0% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$564万 | – | – |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 21.0% | 21.0% | 0.0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $192万 | – | – |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -7.1% | -6.6% | -7.6% |
| Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | – | – | – | -14.5%2024-12-31 | -15.3% | +5.2% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount | – | – | – | $14万 | – | – |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent | – | – | – | -0.5% | – | – |
| Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | – | – | – | -$4.7万 | – | – |
| Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | – | – | – | 0.2% | 0.2% | 0.0% |
| 实际所得税率 | – | – | – | 0.0% | 0.0% | – |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | – | – | – | 0.4%2024-12-31 | 0.4% | 0.0% |
| 应付职工薪酬(流动) | $157万 | $142万 | +10.3% | $175万 | $178万 | -1.4% |
| Estimated Litigation Liability, Current | $102万2026-06-30 | – | – | $02018-12-31 | $130万 | -100.0% |
| Gain (Loss) Related to Litigation Settlement | -$100万2026-06-30 | – | – | -$275万2016-12-31 | -$528万 | +47.9% |
| 一般及行政费用 | $428万 | $287万 | +49.3% | $659万2012-12-31 | $864万 | -23.7% |
| 商誉 | $191万 | $191万 | 0.0% | $191万 | $191万 | 0.0% |
| Goodwill, Impaired, Accumulated Impairment Loss | $02025-12-31 | $0 | – | $0 | $0 | – |
| Goodwill, Impairment Loss | – | – | – | $0 | $0 | – |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | – | – | – | -$957万 | -$954万 | -0.4% |
| Income (Loss) from Continuing Operations before Income Taxes, Foreign | – | – | – | -$1730万 | -$2130万 | +19.0% |
| 税前利润 | – | – | – | -$2690万 | -$3090万 | +13.0% |
| 所得税费用(收益) | – | – | – | $0 | $0 | – |
| 支付的所得税净额 | – | – | – | $0 | $0 | – |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
数据截至 2026-11-21